In the wake of the row between China and India over border in June 2020, India is focusing on self-sufficiency in active pharmaceutical ingredients (API).
Despite being famous in the world for huge potential to produce drugs, China provided the country with half of API it needed in the year 2019. India, also, had to go through disruption for its raw ingredients from China at the beginning of 2020 following the pandemic.
Administrators in pharmaceutical companies including Cadila Healthcare, Biocon, Cipla and Sun Pharmaceutical Industries Ltd. recently announced they aim to cut reliance on China.
In the meantime, Prasad Deshpande, Global Head of Supply Chain and Central Engineering at Biocon pointed to the figures gained last quarter. He said in the quarter India was nearly 50% independent from China. The country’s infrastructure should be bettered to facilitate things to keep up with China.